Tratamento de lesões semelhantes a dermatite atópica em formulações contendo concentrações reduzidas de valerato de betametasona e alfa-tocoferol em nanocarreadores lipídicos

Abstract

Atopic Dermatitis (AD), also known as Atopic Eczema, is a chronic inflammatory skin disease, characterized by intense itching and frequent eczematous lesions, and affects both adults and children. Currently the treatment for AD includes corticosteroids (CS), calcineurin inhibitors and antihistamines that have side effects such as skin thinning and pigmentation changes caused by prolonged use of CS. Nanotechnology therapy and the use of Vitamin E have been applied as a therapeutic option and have shown promise for the treatment of AD. Studies carried out by our group demonstrate that the treatment performed with the combination of Betamethasone Valerate (Bv) and Alpha-tocopherol (A-t) in Nanostructured Lipid Carriers (NLCs) improves the clinical score of AD. The present study evaluated the effects of reducing the concentration of Bv or A-t in NLCs for treating lesions similar to AD, induced by Dinitrochlorobenzene. The use of NLC Bv in reduced concentration of Bv improved disease severity and decreased lesion thickness. However, there was no improvement in the clinical aspects of AD-like lesions in the A-t treated animals. It can be concluded that the of nanocarriers may be fundamental to reduce the concentration of drugs used in the treatment of AD for, reducing significantly the risks of side effects, especially those related to the prolonged use of topical steroids.